BCL2 and lung cancer: The discovery of genetic mutations such as c-Myc, c-Met, Bcl-2, p53, Rb, and other DNA molecular changes associated with lung cancer led to the development of targeted therapies with the potential to improve anti-tumor efficacy while decreasing toxicity [27], however, for most patients with lung cancer these agents did not meet the clinical expectations [28], illustrating the molecular complexity of the disease and the need of a more personalized approach to further optimize treatment [29].